Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) was downgraded by StockNews.com from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Tuesday.
A number of other equities analysts also recently commented on the stock. HC Wainwright restated a “buy” rating and set a $38.00 price objective on shares of Protagonist Therapeutics in a research report on Tuesday, October 10th. JMP Securities upped their price objective on shares of Protagonist Therapeutics from $35.00 to $37.00 and gave the stock a “market outperform” rating in a research report on Friday, November 3rd. Capital One Financial initiated coverage on shares of Protagonist Therapeutics in a research report on Monday, October 30th. They set an “overweight” rating and a $32.00 price objective for the company. Finally, JPMorgan Chase & Co. cut their price objective on shares of Protagonist Therapeutics from $36.00 to $34.00 and set an “overweight” rating for the company in a research report on Monday, September 25th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, Protagonist Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $35.25.
Protagonist Therapeutics Trading Down 0.9 %
Shares of Protagonist Therapeutics stock opened at $22.93 on Tuesday. The company has a fifty day simple moving average of $18.30 and a 200-day simple moving average of $19.25. Protagonist Therapeutics has a 12-month low of $10.57 and a 12-month high of $30.10. The stock has a market cap of $1.32 billion, a price-to-earnings ratio of -8.75 and a beta of 2.02.
Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) last issued its quarterly earnings results on Thursday, November 2nd. The company reported ($0.58) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.10. On average, analysts forecast that Protagonist Therapeutics will post -1.72 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Protagonist Therapeutics
A number of large investors have recently made changes to their positions in PTGX. China Universal Asset Management Co. Ltd. grew its stake in Protagonist Therapeutics by 96.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,473 shares of the company’s stock valued at $25,000 after acquiring an additional 723 shares during the last quarter. Teacher Retirement System of Texas grew its stake in Protagonist Therapeutics by 6.1% in the 3rd quarter. Teacher Retirement System of Texas now owns 12,954 shares of the company’s stock valued at $216,000 after acquiring an additional 740 shares during the last quarter. State Board of Administration of Florida Retirement System grew its stake in Protagonist Therapeutics by 5.9% in the 3rd quarter. State Board of Administration of Florida Retirement System now owns 16,303 shares of the company’s stock valued at $272,000 after acquiring an additional 910 shares during the last quarter. Ameritas Investment Partners Inc. grew its stake in Protagonist Therapeutics by 27.9% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,477 shares of the company’s stock valued at $124,000 after acquiring an additional 976 shares during the last quarter. Finally, Principal Financial Group Inc. boosted its stake in shares of Protagonist Therapeutics by 7.7% during the 3rd quarter. Principal Financial Group Inc. now owns 14,971 shares of the company’s stock worth $250,000 after purchasing an additional 1,068 shares during the last quarter. Hedge funds and other institutional investors own 98.63% of the company’s stock.
About Protagonist Therapeutics
Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of erythrocytosis, iron overload, and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that is in Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist, which is in Phase II clinical trials for inflammatory bowel disease.